RxDoctor Payments Data

Angelo Arcilla

Family Medicine · Daly City, CANPI 1821093394

Payments from drug & device makers

$18,376in general payments, 2019–2025

Across 1,075 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • GSK$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • AbbVie$1K
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$18,365100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,376 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$73,060
Medicare patients
227
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin126$185,505
EliquisApixaban129$136,806
JanuviaSitagliptin Phosphate77$112,789
JanumetSitagliptin Phos/Metformin Hcl48$59,375
RybelsusSemaglutide31$55,019
XareltoRivaroxaban38$52,863
FarxigaDapagliflozin Propanediol38$40,440
LinzessLinaclotide30$25,728
EntrestoSacubitril/Valsartan18$24,935
Atorvastatin Calcium831$24,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,260
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate38$18,242
InvokanaCanagliflozin12$14,325
BreynaBudesonide/Formoterol Fumarate26$12,528
Losartan Potassium637$9,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,744$185,505126 claims
MerckJanuvia, Janumet, Belsomra$594$180,708141 claims
PfizerEliquis$407$136,806129 claims
Johnson & JohnsonXarelto, Invokana$3,092$67,18850 claims
Novo NordiskRybelsus$1,769$55,01931 claims
AstraZenecaFarxiga, Symbicort$1,903$43,75951 claims
AbbVieLinzess$1,190$25,72830 claims
NovartisEntresto$178$24,93518 claims
GSKTrelegy Ellipta$2,131$19,26026 claims
Scilex Pharmaceuticals Inc.Colchicine$42$2,49430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Daly City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →